1. Home
  2. SBGI vs COLL Comparison

SBGI vs COLL Comparison

Compare SBGI & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sinclair Inc.

SBGI

Sinclair Inc.

HOLD

Current Price

$14.09

Market Cap

1.0B

Sector

Industrials

ML Signal

HOLD

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$34.50

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBGI
COLL
Founded
1986
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2023
2015

Fundamental Metrics

Financial Performance
Metric
SBGI
COLL
Price
$14.09
$34.50
Analyst Decision
Buy
Strong Buy
Analyst Count
5
6
Target Price
$21.80
$50.83
AVG Volume (30 Days)
438.9K
400.6K
Earning Date
05-26-2026
05-28-2026
Dividend Yield
7.22%
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.73
Revenue
$3,169,000,000.00
$780,567,000.00
Revenue This Year
$12.59
$6.07
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$20.21
Revenue Growth
N/A
23.62
52 Week Low
$11.89
$23.23
52 Week High
$17.88
$50.79

Technical Indicators

Market Signals
Indicator
SBGI
COLL
Relative Strength Index (RSI) 43.80 16.51
Support Level $12.92 $34.30
Resistance Level $14.32 $36.20
Average True Range (ATR) 0.74 1.59
MACD -0.14 -0.70
Stochastic Oscillator 21.56 2.18

Price Performance

Historical Comparison
SBGI
COLL

About SBGI Sinclair Inc.

Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Share on Social Networks: